Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
697
Active, not recruiting, industry sponsors, Oncology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting1,443
- Completed4,611
697 trials
Showing 1 to 25, recently updated first.
- A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruiting
Syncromune, Inc.Industry
NCT06533644 · 91 participants (planned) · Start May 29, 2025 · Primary completion Apr 14, 2028
Drug: SV-102 · For: Metastatic Castration-resistant Prostate Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 23 sites in all
- A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaActive, not recruiting
Kyowa Kirin Co., Ltd.Industry
NCT07623616 · 6 participants (planned) · Start Apr 23, 2026 · Primary completion Mar 2027
Drug: ziftomenib · For: Acute Myeloid Leukemia (AML)
Sites: Chiba, Japan; Gifu, Japan; Hyōgo, Japan · 20 sites in all
- A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerPivotal-lookingActive, not recruiting
Shanghai Henlius BiotechIndustry
NCT07253142 · 120 participants (planned) · Start Feb 5, 2026 · Primary completion Jun 18, 2027
Drug: HLX43 dose 1; HLX43 dose 2 · For: Non Small Cell Lung Cancer; Small Cell Lung Cancer
Sites: Hefei, China; Fu'zhou, China; Guangzhou, China · 10 sites in all
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerActive, not recruiting
Aulos Bioscience, Inc.Industry
NCT05267626 · 159 participants (planned) · Start Apr 4, 2022 · Primary completion Feb 28, 2027
Drug: AU-007; Aldesleukin and 2 more · For: Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma and 1 more
Sites: Miami, Florida; Grand Rapids, Michigan; Minneapolis, Minnesota · 17 sites in all
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesActive, not recruiting
Pierre Fabre MedicamentIndustry
NCT04554914 · 190 participants (planned) · Start Jul 14, 2021 · Primary completion Jun 2027
Drug: Tabelecleucel · For: Epstein-Barr Virus (EBV)-Associated Diseases; EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD); EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD) and 8 more
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 40 sites in all
- Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsActive, not recruiting
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Industry
NCT05985655 · 230 participants (planned) · Start Jul 6, 2023 · Primary completion Jan 2028
Drug: GTAEXS617; SoC · For: Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC) and 3 more
Sites: Los Angeles, California; Grand Rapids, Michigan; Basking Ridge, New Jersey · 28 sites in all
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid TumorsActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05593094 · 210 participants (planned) · Start Sep 3, 2020 · Primary completion Aug 31, 2027
Drug: ZN-A-1041; ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b and 5 more · For: Advanced Solid Tumors; HER2-positive Breast Cancer
Sites: Tucson, Arizona; Cerritos, California; San Francisco, California · 36 sites in all
- CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.Pivotal-lookingActive, not recruiting
TORL Biotherapeutics, LLCIndustry
NCT06690775 · 230 participants (planned) · Start Nov 20, 2024 · Primary completion Oct 2027
Drug: TORL-1-23; TORL-1-23 and 2 more · For: Epithelial Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancer and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 81 sites in all
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell MalignanciesActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05207670 · 320 participants · Start Feb 1, 2022 · Primary completion Oct 1, 2027
Drug: Mosunetuzumab (Cohorts A-C); Mosunetuzumab (Cohorts D-E) and 1 more · For: Non-Hodgkin Lymphoma
Sites: Mobile, Alabama; Anchorage, Alaska; Phoenix, Arizona · 39 sites in all
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionActive, not recruiting
A2 Biotherapeutics Inc.Industry
NCT06682793 · 240 participants (planned) · Start May 22, 2025 · Primary completion Mar 31, 2029
Drug: A2B395 · For: Solid Tumor, Adult; Colorectal Cancer; Non-Small Cell Lung and 14 more
Sites: Gilbert, Arizona; Phoenix, Arizona; La Jolla, California · 13 sites in all
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03431350 · 136 participants · Start Mar 2, 2018 · Primary completion Aug 31, 2021
Drug: Niraparib 200 mg; Cetrelimab 240 mg and 3 more · For: Prostatic Neoplasms, Castration-Resistant
Sites: Tucson, Arizona; Denver, Colorado; Jacksonville, Florida · 50 sites in all
- Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsActive, not recruiting
Tango Therapeutics, Inc.Industry
NCT05887492 · 126 participants (planned) · Start Jun 12, 2023 · Primary completion Sep 22, 2026
Drug: TNG260; Pembrolizumab · For: Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer and 1 more
Sites: Santa Monica, California; Denver, Colorado; Sarasota, Florida · 13 sites in all
- An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial CancerActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02365597 · 239 participants · Start Apr 22, 2015 · Primary completion Sep 15, 2022
Drug: Erdafitinib; Midazolam and 1 more · For: Urothelial Cancer
Sites: Sedona, Arizona; Los Angeles, California; Orange, California · 105 sites in all
- A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 ExpressionActive, not recruiting
A2 Biotherapeutics Inc.Industry
NCT06051695 · 474 participants (planned) · Start Apr 3, 2024 · Primary completion Jun 2028
Drug: A2B694; A2B543 · For: Solid Tumor, Adult; Colorectal Cancer; NSCLC and 17 more
Sites: Gilbert, Arizona; La Jolla, California; Los Angeles, California · 12 sites in all
- A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07047118 · 138 participants · Start Jul 3, 2025 · Primary completion Jul 16, 2027
Drug: JSB462; AAA617 · For: Prostatic Cancer, Castration-Resistant
Sites: Duarte, California; Santa Monica, California; Denver, Colorado · 44 sites in all
- An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06991556 · 168 participants · Start Jul 7, 2025 · Primary completion Dec 3, 2026
Drug: JSB462; Abiraterone and 1 more · For: Metastatic Hormone-sensitive Prostate Cancer
Sites: La Jolla, California; Santa Monica, California; Denver, Colorado · 64 sites in all
- Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06788912 · 60 participants (planned) · Start Mar 20, 2025 · Primary completion Feb 6, 2032
Drug: Pembrolizumab (neoadjuvant); Cisplatin and 11 more · For: Lung Neoplasm Malignant
Sites: Daphne, Alabama; Santa Barbara, California; Lone Tree, Colorado · 39 sites in all
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06353386 · 220 participants (planned) · Start May 20, 2024 · Primary completion Jan 15, 2029
Drug: Opevesostat; Olaparib and 5 more · For: Prostatic Neoplasms, Castration-Resistant
Sites: La Jolla, California; Los Angeles, California; Miami, Florida · 77 sites in all
- IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCPivotal-lookingActive, not recruiting
InxMed (Shanghai) Co., Ltd.Industry
NCT05994131 · 110 participants (planned) · Start Jul 13, 2023 · Primary completion Sep 20, 2025
Drug: IN10018; Furmonertinib · For: NSCLC
Sites: Shanghai, China
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03742102 · 243 participants · Start Dec 21, 2018 · Primary completion Nov 29, 2024
Drug: Durvalumab; Capivasertib and 4 more · For: Triple Negative Breast Neoplasms
Sites: Tucson, Arizona; Columbia, Maryland; Boston, Massachusetts · 32 sites in all
- An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPCActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06894511 · 7 participants · Start Sep 11, 2025 · Primary completion Nov 17, 2026
Drug: AAA617; ARPI: Abiraterone and 1 more · For: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Sites: Casa Grande, Arizona; Gilbert, Arizona; Newport Beach, California · 5 sites in all
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid TumorsPivotal-lookingActive, not recruiting
InxMed (Shanghai) Co., Ltd.Industry
NCT06166836 · 140 participants (planned) · Start Oct 12, 2022 · Primary completion Dec 31, 2027
Drug: D1553; IN10018(Ifebemtinib) · For: Solid Tumor
Sites: Hangzhou, China; Bengbu, China; Changsha, China · 10 sites in all
- IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerActive, not recruiting
InxMed (Shanghai) Co., Ltd.Industry
NCT05827796 · 70 participants (planned) · Start Dec 8, 2022 · Primary completion Oct 11, 2025
Drug: IN10018; Albumin-Bound Paclitaxel and 2 more · For: Pancreatic Cancer
Sites: Shanghai, China
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS TumorsActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04774718 · 42 participants (planned) · Start Sep 14, 2021 · Primary completion Feb 28, 2032
Drug: Alectinib · For: ALK Fusion-positive Solid or CNS Tumors
Sites: Palo Alto, California; St. Petersburg, Florida; Ann Arbor, Michigan · 30 sites in all
- To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCPivotal-lookingActive, not recruiting
Shanghai Henlius BiotechIndustry
NCT05468489 · 200 participants (planned) · Start Nov 18, 2022 · Primary completion Feb 28, 2026
Drug: Serplulimab + chemotherapy (carboplatin-etoposide); Atezolizumab + chemotherapy (carboplatin-etoposide) · For: Extensive Stage Small Cell Lung Cancer
Sites: Birmingham, Alabama; Goodyear, Arizona; Tucson, Arizona · 65 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.